All In Biotech

Drug Trial Radar · NCT07474727

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

An Phase II Study Evaluating the Safety and Efficacy of AMT-676 in Combination With 5-fluorouracil, Leucovorin, Bevacizumab (or Cetuximab) in Participants of Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

Sep 30, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Multitude Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.

Conditions

  • Colorectal Cancer

Interventions

  • AMT-676Drug

    Patients will get different dose levels treatment of AMT-676. AMT-676 will be Administered as an intravenous (IV) infusion every 2 weeks (Q2W) .

  • 5-FUDrug

    5-FU 400 mg/m\^2 IV bolus on day 1, followed by 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion, q2w

  • LeucovorinDrug

    Leucovorin 400 mg/m\^2 IV day 1, q2w

  • BevacizumabDrug

    Bevacizumab 5 mg/kg IV, day 1

  • CetuximabDrug

    Cetuximab 500 mg/m\^2 IV over 2 hours, day 1, q2w

  • IrinotecanDrug

    Irinotecan 180 mg/m\^2 IV, day 1

  • OxaliplatinDrug

    Oxaliplatin 85 mg/m\^2 IV, day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE & SAETime frame: 30 days after the last treatment
  2. MTDTime frame: 28 days after first dose
  3. DLTsTime frame: 28 days after first dose
  4. ORRTime frame: through study completion, an average of 18 months
  5. PFSTime frame: through study completion, an average of 18 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Gaungxi, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Not yet recruiting

  • Wuhan Union Hospital of China

    Wuhan, Hubei, China · Not yet recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Liaoning Cancer Hospital & Institute

    Shengyang, Liaoning, China · Not yet recruiting

  • Shandong Cancer Hospital and Institute

    Jinan, Shandong, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.